BRAF and neoplasm: Our results were slightly different from a previous study by You et al.28They reported that primary tumor locations could predict the clinical prognosis of bevacizumab‐treated patients with RAS/BRAF‐wild mCRC and that bevacizumab combined with FOLFIRI regimen was more suitable for patients with left‐sided mCRC.